Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators. Ramos F, et al. Among authors: seegers v. Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31. Leuk Res. 2015. PMID: 25601157
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Thepot S, et al. Among authors: seegers v. Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7. Leuk Res. 2014. PMID: 25449687 Clinical Trial.
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators. Falantes J, et al. Among authors: seegers v. Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24. Leuk Lymphoma. 2018. PMID: 28838276
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Thepot S, et al. Among authors: seegers v. Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27. Blood. 2010. PMID: 20664061 Free article. Clinical Trial.
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS). Thépot S, et al. Among authors: seegers v. Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6. Am J Hematol. 2014. PMID: 24375487 Free article.
Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages toward an Inflammatory Protumor Phenotype.
Paolini L, Adam C, Beauvillain C, Preisser L, Blanchard S, Pignon P, Seegers V, Chevalier LM, Campone M, Wernert R, Verrielle V, Raro P, Ifrah N, Lavoué V, Descamps P, Morel A, Catros V, Tcherkez G, Lenaers G, Bocca C, Kouassi Nzoughet J, Procaccio V, Delneste Y, Jeannin P. Paolini L, et al. Among authors: seegers v. Cancer Immunol Res. 2020 Mar;8(3):383-395. doi: 10.1158/2326-6066.CIR-18-0749. Epub 2020 Jan 10. Cancer Immunol Res. 2020. PMID: 31924656 Free article.
Assessing physicians' and nurses' experience of dying and death in the ICU: development of the CAESAR-P and the CAESAR-N instruments.
Boissier F, Seegers V, Seguin A, Legriel S, Cariou A, Jaber S, Lefrant JY, Rimmelé T, Renault A, Vinatier I, Mathonnet A, Reuter D, Guisset O, Cracco C, Durand-Gasselin J, Éon B, Thirion M, Rigaud JP, Philippon-Jouve B, Argaud L, Chouquer R, Papazian L, Dedrie C, Georges H, Lebas E, Rolin N, Bollaert PE, Lecuyer L, Viquesnel G, Leone M, Chalumeau-Lemoine L, Garrouste-Orgeas M, Azoulay E, Kentish-Barnes N. Boissier F, et al. Among authors: seegers v. Crit Care. 2020 Aug 25;24(1):521. doi: 10.1186/s13054-020-03191-z. Crit Care. 2020. PMID: 32843097 Free PMC article.
CAESAR: a new tool to assess relatives' experience of dying and death in the ICU.
Kentish-Barnes N, Seegers V, Legriel S, Cariou A, Jaber S, Lefrant JY, Floccard B, Renault A, Vinatier I, Mathonnet A, Reuter D, Guisset O, Cracco C, Seguin A, Durand-Gasselin J, Éon B, Thirion M, Rigaud JP, Philippon-Jouve B, Argaud L, Chouquer R, Adda M, Papazian L, Dedrie C, Georges H, Lebas E, Rolin N, Bollaert PE, Lecuyer L, Viquesnel G, Léone M, Chalumeau-Lemoine L, Cohen-Solal Z, Garrouste-Orgeas M, Tamion F, Falissard B, Chevret S, Azoulay E. Kentish-Barnes N, et al. Among authors: seegers v. Intensive Care Med. 2016 Jun;42(6):995-1002. doi: 10.1007/s00134-016-4260-4. Epub 2016 Mar 7. Intensive Care Med. 2016. PMID: 26951427
66 results